| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 115 | 2025 | 383 | 24.370 |
Why?
|
| Hypertension, Pulmonary | 157 | 2024 | 1876 | 17.570 |
Why?
|
| Nitric Oxide | 116 | 2023 | 892 | 12.050 |
Why?
|
| Lung | 134 | 2025 | 3925 | 10.650 |
Why?
|
| Persistent Fetal Circulation Syndrome | 49 | 2023 | 137 | 10.320 |
Why?
|
| Infant, Premature | 77 | 2025 | 540 | 9.290 |
Why?
|
| Pulmonary Circulation | 78 | 2022 | 429 | 7.870 |
Why?
|
| Infant, Newborn | 206 | 2025 | 5704 | 5.980 |
Why?
|
| Pulmonary Artery | 74 | 2021 | 1091 | 5.960 |
Why?
|
| Pulmonary Alveoli | 30 | 2023 | 403 | 5.770 |
Why?
|
| Animals, Newborn | 57 | 2024 | 813 | 4.630 |
Why?
|
| Fetus | 58 | 2019 | 764 | 4.370 |
Why?
|
| Sheep | 94 | 2018 | 832 | 4.090 |
Why?
|
| Vascular Resistance | 51 | 2024 | 373 | 3.850 |
Why?
|
| Respiratory Insufficiency | 21 | 2023 | 316 | 3.540 |
Why?
|
| Pediatrics | 20 | 2024 | 1060 | 3.450 |
Why?
|
| Vasodilator Agents | 22 | 2023 | 325 | 3.400 |
Why?
|
| Hyperoxia | 11 | 2024 | 97 | 3.400 |
Why?
|
| Vascular Endothelial Growth Factor A | 25 | 2023 | 528 | 3.340 |
Why?
|
| Respiration, Artificial | 36 | 2025 | 594 | 3.160 |
Why?
|
| Administration, Inhalation | 77 | 2023 | 675 | 3.120 |
Why?
|
| Nitric Oxide Synthase | 34 | 2007 | 238 | 3.060 |
Why?
|
| Lung Diseases | 20 | 2024 | 755 | 2.900 |
Why?
|
| Vasodilation | 36 | 2011 | 480 | 2.820 |
Why?
|
| Infant, Premature, Diseases | 11 | 2023 | 95 | 2.730 |
Why?
|
| Neovascularization, Physiologic | 15 | 2015 | 179 | 2.630 |
Why?
|
| Premature Birth | 11 | 2024 | 313 | 2.560 |
Why?
|
| Racism | 5 | 2022 | 129 | 2.540 |
Why?
|
| Hypoxia | 35 | 2023 | 1070 | 2.420 |
Why?
|
| Endothelial Cells | 20 | 2024 | 734 | 2.360 |
Why?
|
| Hemodynamics | 53 | 2022 | 1095 | 2.350 |
Why?
|
| Humans | 325 | 2025 | 128896 | 2.290 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 15 | 2021 | 105 | 2.250 |
Why?
|
| Pregnancy | 84 | 2024 | 6247 | 2.220 |
Why?
|
| Infant | 95 | 2025 | 8994 | 2.190 |
Why?
|
| Endothelium, Vascular | 22 | 2024 | 917 | 2.130 |
Why?
|
| rho-Associated Kinases | 7 | 2016 | 83 | 2.060 |
Why?
|
| Gestational Age | 40 | 2025 | 857 | 2.050 |
Why?
|
| Vascular Diseases | 8 | 2023 | 241 | 2.010 |
Why?
|
| Social Justice | 3 | 2020 | 78 | 2.000 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 16 | 2024 | 204 | 1.930 |
Why?
|
| Lung Injury | 5 | 2024 | 214 | 1.930 |
Why?
|
| Oxygen | 31 | 2023 | 912 | 1.910 |
Why?
|
| Endothelin-1 | 17 | 2016 | 179 | 1.870 |
Why?
|
| Animals | 159 | 2024 | 34628 | 1.860 |
Why?
|
| Infant, Extremely Premature | 8 | 2023 | 60 | 1.840 |
Why?
|
| Rats | 42 | 2024 | 5236 | 1.800 |
Why?
|
| Endotoxins | 9 | 2024 | 221 | 1.800 |
Why?
|
| Oxygen Inhalation Therapy | 15 | 2019 | 146 | 1.720 |
Why?
|
| Rats, Sprague-Dawley | 31 | 2024 | 2308 | 1.670 |
Why?
|
| Female | 189 | 2025 | 68162 | 1.640 |
Why?
|
| Nitric Oxide Synthase Type III | 26 | 2016 | 204 | 1.530 |
Why?
|
| Ductus Arteriosus | 19 | 2012 | 72 | 1.490 |
Why?
|
| Sulfones | 7 | 2013 | 107 | 1.480 |
Why?
|
| Phosphodiesterase Inhibitors | 9 | 2019 | 85 | 1.440 |
Why?
|
| Indoles | 10 | 2024 | 378 | 1.400 |
Why?
|
| Societies, Medical | 6 | 2024 | 760 | 1.370 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 9 | 2020 | 109 | 1.360 |
Why?
|
| Chorioamnionitis | 5 | 2024 | 38 | 1.350 |
Why?
|
| High-Frequency Ventilation | 14 | 2002 | 45 | 1.350 |
Why?
|
| Piperazines | 7 | 2013 | 326 | 1.350 |
Why?
|
| Cyclic GMP | 11 | 2011 | 85 | 1.330 |
Why?
|
| Guanylate Cyclase | 6 | 2022 | 33 | 1.310 |
Why?
|
| Cardiac Catheterization | 18 | 2024 | 583 | 1.290 |
Why?
|
| Endothelins | 13 | 2009 | 61 | 1.290 |
Why?
|
| Fetal Blood | 6 | 2017 | 315 | 1.290 |
Why?
|
| Child | 73 | 2024 | 20824 | 1.280 |
Why?
|
| Mentors | 3 | 2021 | 174 | 1.260 |
Why?
|
| Bronchodilator Agents | 12 | 2019 | 252 | 1.230 |
Why?
|
| Child Health | 2 | 2020 | 145 | 1.230 |
Why?
|
| Vitamin D | 5 | 2020 | 384 | 1.220 |
Why?
|
| Health Status Disparities | 2 | 2020 | 242 | 1.160 |
Why?
|
| Fetal Diseases | 10 | 2007 | 148 | 1.140 |
Why?
|
| Disease Models, Animal | 27 | 2024 | 3994 | 1.130 |
Why?
|
| Social Determinants of Health | 2 | 2020 | 214 | 1.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2017 | 102 | 1.120 |
Why?
|
| Receptors, Endothelin | 9 | 2016 | 50 | 1.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 5 | 2022 | 70 | 1.090 |
Why?
|
| Pulmonary Medicine | 5 | 2021 | 79 | 1.080 |
Why?
|
| Pulmonary Veins | 6 | 2014 | 95 | 1.020 |
Why?
|
| Male | 116 | 2025 | 63146 | 1.010 |
Why?
|
| Echocardiography, Doppler | 4 | 2018 | 111 | 1.010 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2019 | 68 | 1.000 |
Why?
|
| Hernia, Diaphragmatic | 10 | 2014 | 69 | 0.980 |
Why?
|
| Vasoconstriction | 9 | 2008 | 195 | 0.980 |
Why?
|
| Endothelin Receptor Antagonists | 7 | 2013 | 62 | 0.960 |
Why?
|
| Down Syndrome | 5 | 2022 | 454 | 0.960 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 15 | 0.950 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 570 | 0.910 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2023 | 30 | 0.910 |
Why?
|
| Hypertrophy, Right Ventricular | 15 | 2016 | 145 | 0.910 |
Why?
|
| Stem Cells | 5 | 2013 | 572 | 0.910 |
Why?
|
| Respiratory Tract Diseases | 3 | 2019 | 151 | 0.900 |
Why?
|
| Dipyridamole | 7 | 1998 | 25 | 0.900 |
Why?
|
| Immunohistochemistry | 16 | 2020 | 1694 | 0.890 |
Why?
|
| Surface Plasmon Resonance | 2 | 2021 | 87 | 0.880 |
Why?
|
| Infant, Low Birth Weight | 4 | 2020 | 134 | 0.860 |
Why?
|
| Child, Preschool | 47 | 2024 | 10457 | 0.860 |
Why?
|
| Signal Transduction | 22 | 2021 | 4857 | 0.850 |
Why?
|
| Sildenafil Citrate | 9 | 2021 | 59 | 0.850 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2023 | 308 | 0.820 |
Why?
|
| Muscle, Smooth, Vascular | 10 | 2009 | 430 | 0.820 |
Why?
|
| Physicians | 3 | 2018 | 846 | 0.820 |
Why?
|
| Nitroarginine | 19 | 2007 | 57 | 0.790 |
Why?
|
| Placenta | 7 | 2024 | 706 | 0.790 |
Why?
|
| Pulmonary Surfactants | 6 | 2024 | 108 | 0.780 |
Why?
|
| Pulmonary Gas Exchange | 10 | 2022 | 119 | 0.780 |
Why?
|
| Career Choice | 3 | 2014 | 211 | 0.780 |
Why?
|
| Heart Ventricles | 5 | 2021 | 778 | 0.770 |
Why?
|
| Child Welfare | 2 | 2014 | 208 | 0.770 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2013 | 104 | 0.760 |
Why?
|
| Lung Compliance | 2 | 2020 | 46 | 0.760 |
Why?
|
| Vitamin D Deficiency | 3 | 2020 | 179 | 0.760 |
Why?
|
| Cystic Fibrosis | 15 | 2021 | 1061 | 0.750 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2022 | 387 | 0.750 |
Why?
|
| Bronchial Arteries | 2 | 2018 | 12 | 0.750 |
Why?
|
| Precision Medicine | 2 | 2023 | 385 | 0.750 |
Why?
|
| Echocardiography | 14 | 2024 | 634 | 0.730 |
Why?
|
| Disease Management | 4 | 2019 | 594 | 0.720 |
Why?
|
| Peptide PHI | 1 | 2020 | 3 | 0.720 |
Why?
|
| Enzyme Activation | 5 | 2012 | 811 | 0.720 |
Why?
|
| Early Diagnosis | 3 | 2021 | 232 | 0.710 |
Why?
|
| Chronic Disease | 22 | 2019 | 1715 | 0.710 |
Why?
|
| Glycogen Storage Disease | 1 | 2020 | 19 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 4 | 2015 | 293 | 0.700 |
Why?
|
| Benzoates | 2 | 2011 | 40 | 0.700 |
Why?
|
| Pregnancy, Animal | 1 | 2020 | 53 | 0.690 |
Why?
|
| Phenotype | 12 | 2025 | 3059 | 0.690 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 151 | 0.690 |
Why?
|
| Trachea | 5 | 2017 | 228 | 0.680 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2020 | 75 | 0.680 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 3 | 2021 | 17 | 0.680 |
Why?
|
| Bleomycin | 4 | 2016 | 241 | 0.680 |
Why?
|
| Hypertension | 5 | 2023 | 1236 | 0.680 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 16 | 0.680 |
Why?
|
| Pyrroles | 9 | 2020 | 201 | 0.670 |
Why?
|
| Serotonin | 2 | 2013 | 321 | 0.670 |
Why?
|
| Heart Defects, Congenital | 15 | 2024 | 752 | 0.670 |
Why?
|
| Blotting, Western | 13 | 2020 | 1188 | 0.670 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 123 | 0.660 |
Why?
|
| Familial Primary Pulmonary Hypertension | 8 | 2023 | 197 | 0.660 |
Why?
|
| Birth Weight | 5 | 2020 | 493 | 0.660 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 20 | 0.660 |
Why?
|
| Postnatal Care | 1 | 2020 | 71 | 0.650 |
Why?
|
| Cells, Cultured | 17 | 2016 | 4048 | 0.640 |
Why?
|
| Vascular Stiffness | 5 | 2019 | 479 | 0.640 |
Why?
|
| Health Equity | 1 | 2020 | 76 | 0.640 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2016 | 34 | 0.640 |
Why?
|
| Pyridines | 6 | 2012 | 472 | 0.630 |
Why?
|
| Enzyme Inhibitors | 16 | 2009 | 827 | 0.630 |
Why?
|
| Emphysema | 1 | 2020 | 110 | 0.630 |
Why?
|
| Biomedical Research | 5 | 2014 | 654 | 0.620 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 210 | 0.610 |
Why?
|
| Prospective Studies | 19 | 2025 | 7060 | 0.610 |
Why?
|
| Arteriovenous Anastomosis | 3 | 2022 | 13 | 0.610 |
Why?
|
| United States | 23 | 2024 | 13975 | 0.610 |
Why?
|
| Respiratory Function Tests | 10 | 2025 | 596 | 0.610 |
Why?
|
| Acetylcholine | 11 | 2009 | 185 | 0.610 |
Why?
|
| Blood Pressure | 28 | 2019 | 1743 | 0.610 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 4 | 2016 | 28 | 0.600 |
Why?
|
| Protein Precursors | 6 | 2000 | 126 | 0.600 |
Why?
|
| Science | 2 | 2016 | 53 | 0.600 |
Why?
|
| Vitamins | 6 | 2019 | 171 | 0.600 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 487 | 0.600 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2017 | 544 | 0.600 |
Why?
|
| Superoxide Dismutase | 5 | 2015 | 328 | 0.580 |
Why?
|
| Pulmonary Emphysema | 2 | 2020 | 278 | 0.580 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 613 | 0.580 |
Why?
|
| Bone Marrow Cells | 3 | 2009 | 291 | 0.580 |
Why?
|
| Longevity | 1 | 2018 | 150 | 0.570 |
Why?
|
| Epoprostenol | 5 | 2021 | 135 | 0.560 |
Why?
|
| Cardiology | 1 | 2020 | 281 | 0.550 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 8 | 2015 | 86 | 0.550 |
Why?
|
| Fetal Growth Retardation | 6 | 2022 | 542 | 0.550 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2016 | 816 | 0.550 |
Why?
|
| Exosomes | 1 | 2018 | 95 | 0.540 |
Why?
|
| Collagen Type VIII | 1 | 2016 | 3 | 0.540 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2016 | 7 | 0.540 |
Why?
|
| Infant Care | 1 | 2016 | 46 | 0.530 |
Why?
|
| Collagen Type IV | 1 | 2016 | 22 | 0.530 |
Why?
|
| Respiration Disorders | 4 | 2019 | 73 | 0.530 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 162 | 0.530 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 259 | 0.530 |
Why?
|
| Estradiol | 4 | 2001 | 494 | 0.530 |
Why?
|
| Vascular Endothelial Growth Factors | 6 | 2022 | 76 | 0.530 |
Why?
|
| Pulmonary Wedge Pressure | 7 | 2022 | 67 | 0.520 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2016 | 61 | 0.520 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 559 | 0.520 |
Why?
|
| Pre-Eclampsia | 3 | 2022 | 183 | 0.520 |
Why?
|
| Academies and Institutes | 1 | 2016 | 47 | 0.520 |
Why?
|
| Hospitalization | 4 | 2015 | 2080 | 0.510 |
Why?
|
| Organ Size | 10 | 2009 | 446 | 0.510 |
Why?
|
| Endothelial Growth Factors | 4 | 2003 | 63 | 0.510 |
Why?
|
| Bronchi | 5 | 2021 | 253 | 0.500 |
Why?
|
| PPAR gamma | 2 | 2013 | 182 | 0.500 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 6 | 2006 | 17 | 0.500 |
Why?
|
| Lymphokines | 4 | 2003 | 126 | 0.500 |
Why?
|
| Altitude | 3 | 2022 | 451 | 0.500 |
Why?
|
| Congresses as Topic | 2 | 2014 | 217 | 0.500 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 18 | 0.500 |
Why?
|
| Primary Prevention | 2 | 2014 | 191 | 0.500 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 473 | 0.490 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 509 | 0.490 |
Why?
|
| Pulmonary Edema | 4 | 2008 | 105 | 0.490 |
Why?
|
| Follow-Up Studies | 16 | 2025 | 4917 | 0.490 |
Why?
|
| Receptors, Calcitriol | 1 | 2015 | 53 | 0.490 |
Why?
|
| Risk | 8 | 2021 | 866 | 0.490 |
Why?
|
| Retrospective Studies | 35 | 2025 | 14546 | 0.490 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 238 | 0.480 |
Why?
|
| Faculty, Medical | 1 | 2018 | 263 | 0.480 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2025 | 226 | 0.480 |
Why?
|
| Endpoint Determination | 1 | 2015 | 76 | 0.480 |
Why?
|
| Capillaries | 2 | 2015 | 98 | 0.480 |
Why?
|
| Registries | 5 | 2024 | 1916 | 0.480 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2021 | 181 | 0.470 |
Why?
|
| Cooperative Behavior | 2 | 2022 | 427 | 0.470 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 155 | 0.470 |
Why?
|
| Early Medical Intervention | 2 | 2014 | 59 | 0.470 |
Why?
|
| Radiology | 1 | 2017 | 160 | 0.460 |
Why?
|
| Tracheostomy | 6 | 2025 | 119 | 0.460 |
Why?
|
| Adventitia | 1 | 2014 | 41 | 0.460 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 594 | 0.450 |
Why?
|
| Patient Care Team | 5 | 2024 | 605 | 0.450 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2017 | 108 | 0.450 |
Why?
|
| Mentoring | 1 | 2016 | 120 | 0.450 |
Why?
|
| Treatment Outcome | 26 | 2024 | 10239 | 0.440 |
Why?
|
| Smoking | 3 | 2018 | 1501 | 0.440 |
Why?
|
| Internship and Residency | 2 | 2014 | 1052 | 0.440 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 50 | 0.440 |
Why?
|
| Risk Factors | 19 | 2024 | 9792 | 0.440 |
Why?
|
| Extracorporeal Membrane Oxygenation | 13 | 2015 | 281 | 0.440 |
Why?
|
| Hyaline Membrane Disease | 4 | 1998 | 20 | 0.440 |
Why?
|
| Body Weight | 12 | 2009 | 931 | 0.440 |
Why?
|
| Ventricular Dysfunction, Right | 5 | 2019 | 226 | 0.430 |
Why?
|
| Pyrazoles | 3 | 2006 | 403 | 0.430 |
Why?
|
| Isoenzymes | 3 | 2011 | 303 | 0.430 |
Why?
|
| Purines | 6 | 2013 | 170 | 0.430 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 246 | 0.430 |
Why?
|
| Time Factors | 21 | 2021 | 6568 | 0.430 |
Why?
|
| Autoantigens | 1 | 2016 | 410 | 0.430 |
Why?
|
| Gene Expression | 5 | 2023 | 1476 | 0.420 |
Why?
|
| Arterial Pressure | 3 | 2019 | 118 | 0.420 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2013 | 19 | 0.420 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 106 | 0.420 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2006 | 172 | 0.410 |
Why?
|
| Betamethasone | 2 | 2024 | 20 | 0.410 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 2767 | 0.410 |
Why?
|
| T-Box Domain Proteins | 3 | 2023 | 95 | 0.410 |
Why?
|
| Ventricular Function, Right | 6 | 2021 | 274 | 0.410 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2003 | 376 | 0.400 |
Why?
|
| Blood Vessels | 4 | 2016 | 184 | 0.400 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 95 | 0.400 |
Why?
|
| Umbilical Cord | 1 | 2013 | 84 | 0.400 |
Why?
|
| Forkhead Transcription Factors | 3 | 2023 | 182 | 0.400 |
Why?
|
| Reference Values | 9 | 2020 | 791 | 0.400 |
Why?
|
| Amides | 3 | 2012 | 91 | 0.390 |
Why?
|
| Potassium Channels | 3 | 2000 | 139 | 0.390 |
Why?
|
| Vasomotor System | 6 | 2002 | 43 | 0.390 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 2013 | 0.390 |
Why?
|
| Age Factors | 11 | 2019 | 3133 | 0.380 |
Why?
|
| MicroRNAs | 1 | 2018 | 668 | 0.380 |
Why?
|
| In Vitro Techniques | 6 | 2020 | 1061 | 0.370 |
Why?
|
| Embryonic and Fetal Development | 7 | 2002 | 95 | 0.370 |
Why?
|
| Mothers | 1 | 2017 | 723 | 0.360 |
Why?
|
| Organogenesis | 1 | 2011 | 57 | 0.360 |
Why?
|
| History, 20th Century | 3 | 2017 | 294 | 0.360 |
Why?
|
| Cell Proliferation | 8 | 2015 | 2337 | 0.350 |
Why?
|
| Adolescent | 27 | 2024 | 20197 | 0.350 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2018 | 106 | 0.350 |
Why?
|
| Prostaglandins | 4 | 2007 | 85 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 1968 | 0.340 |
Why?
|
| Risk Assessment | 9 | 2024 | 3286 | 0.340 |
Why?
|
| Atrial Natriuretic Factor | 3 | 1996 | 56 | 0.340 |
Why?
|
| Home Care Services | 3 | 2024 | 246 | 0.340 |
Why?
|
| Cultural Diversity | 2 | 2020 | 62 | 0.330 |
Why?
|
| Culturally Competent Care | 2 | 2020 | 56 | 0.330 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 278 | 0.330 |
Why?
|
| Health Status Indicators | 2 | 2020 | 168 | 0.330 |
Why?
|
| Piperidines | 3 | 2016 | 186 | 0.330 |
Why?
|
| Survival Rate | 11 | 2017 | 1884 | 0.320 |
Why?
|
| Oligopeptides | 3 | 2016 | 256 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 420 | 0.320 |
Why?
|
| Calcium Channel Blockers | 3 | 2007 | 125 | 0.310 |
Why?
|
| Regional Blood Flow | 6 | 2021 | 462 | 0.310 |
Why?
|
| Adult | 24 | 2023 | 35361 | 0.310 |
Why?
|
| Endothelium | 3 | 2015 | 114 | 0.300 |
Why?
|
| Patient Discharge | 4 | 2025 | 858 | 0.300 |
Why?
|
| Ventilator Weaning | 4 | 2024 | 35 | 0.300 |
Why?
|
| Arginine | 7 | 1994 | 254 | 0.300 |
Why?
|
| Aorta | 7 | 2017 | 410 | 0.300 |
Why?
|
| RNA, Messenger | 12 | 2014 | 2700 | 0.300 |
Why?
|
| Endothelin B Receptor Antagonists | 2 | 2005 | 11 | 0.290 |
Why?
|
| Phenyl Ethers | 1 | 2007 | 4 | 0.290 |
Why?
|
| Receptors, Growth Factor | 3 | 2002 | 55 | 0.290 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2002 | 234 | 0.290 |
Why?
|
| Iloprost | 1 | 2008 | 46 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2008 | 870 | 0.290 |
Why?
|
| Recombinant Proteins | 6 | 2006 | 1304 | 0.280 |
Why?
|
| Fluorocarbons | 2 | 1999 | 109 | 0.280 |
Why?
|
| Steroids | 3 | 2024 | 148 | 0.280 |
Why?
|
| Home Nursing | 3 | 2003 | 26 | 0.280 |
Why?
|
| Cohort Studies | 10 | 2024 | 5394 | 0.280 |
Why?
|
| Biomarkers | 6 | 2020 | 3874 | 0.270 |
Why?
|
| Labor, Obstetric | 2 | 2001 | 55 | 0.270 |
Why?
|
| Oxadiazoles | 3 | 2011 | 35 | 0.270 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2023 | 50 | 0.270 |
Why?
|
| Positive-Pressure Respiration | 4 | 2023 | 75 | 0.270 |
Why?
|
| Neonatal Screening | 7 | 1993 | 161 | 0.270 |
Why?
|
| Ligation | 5 | 2012 | 87 | 0.260 |
Why?
|
| Respiratory Sounds | 2 | 2025 | 121 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 379 | 0.260 |
Why?
|
| Disease Progression | 5 | 2018 | 2603 | 0.260 |
Why?
|
| Asthma | 2 | 2021 | 2258 | 0.260 |
Why?
|
| Receptor, Endothelin B | 6 | 2004 | 55 | 0.250 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 760 | 0.250 |
Why?
|
| Prognosis | 10 | 2019 | 3787 | 0.250 |
Why?
|
| Antigens, CD | 1 | 2008 | 479 | 0.250 |
Why?
|
| Glucocorticoids | 2 | 2000 | 570 | 0.250 |
Why?
|
| Logistic Models | 4 | 2020 | 1963 | 0.250 |
Why?
|
| Research Personnel | 3 | 2020 | 161 | 0.250 |
Why?
|
| Sulfonamides | 5 | 2016 | 494 | 0.240 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 39 | 0.240 |
Why?
|
| Monitoring, Physiologic | 4 | 2019 | 265 | 0.240 |
Why?
|
| Tracheobronchomalacia | 1 | 2025 | 14 | 0.240 |
Why?
|
| Blotting, Northern | 6 | 2002 | 202 | 0.240 |
Why?
|
| Amniotic Fluid | 3 | 2018 | 79 | 0.240 |
Why?
|
| Apoptosis | 4 | 2013 | 2481 | 0.240 |
Why?
|
| Bacteria | 1 | 2011 | 812 | 0.240 |
Why?
|
| Morbidity | 2 | 2023 | 301 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 739 | 0.240 |
Why?
|
| Ventricular Function, Left | 4 | 2017 | 526 | 0.240 |
Why?
|
| Antioxidants | 3 | 2013 | 557 | 0.230 |
Why?
|
| Peptides, Cyclic | 5 | 2016 | 258 | 0.230 |
Why?
|
| History, 21st Century | 2 | 2017 | 182 | 0.230 |
Why?
|
| Analysis of Variance | 7 | 2012 | 1283 | 0.230 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1213 | 0.230 |
Why?
|
| Consensus | 2 | 2024 | 644 | 0.220 |
Why?
|
| Respiratory Therapy | 2 | 1994 | 23 | 0.220 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 266 | 0.220 |
Why?
|
| Asperger Syndrome | 1 | 2023 | 7 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3348 | 0.220 |
Why?
|
| Syndrome | 1 | 2024 | 342 | 0.220 |
Why?
|
| Neonatology | 1 | 2024 | 22 | 0.220 |
Why?
|
| Fetal Development | 3 | 2022 | 283 | 0.220 |
Why?
|
| Prenatal Care | 3 | 2020 | 272 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1523 | 0.210 |
Why?
|
| Models, Animal | 2 | 2020 | 370 | 0.210 |
Why?
|
| Lung Transplantation | 4 | 2024 | 276 | 0.210 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 108 | 0.210 |
Why?
|
| Respiratory System Agents | 1 | 2023 | 22 | 0.210 |
Why?
|
| Physicians, Women | 2 | 2014 | 69 | 0.210 |
Why?
|
| Periodicals as Topic | 2 | 2017 | 209 | 0.210 |
Why?
|
| Placenta Growth Factor | 2 | 2022 | 23 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 140 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 392 | 0.200 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 89 | 0.200 |
Why?
|
| Fatal Outcome | 4 | 2018 | 301 | 0.200 |
Why?
|
| Ketanserin | 2 | 2013 | 12 | 0.200 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.200 |
Why?
|
| Oxidative Stress | 3 | 2018 | 1220 | 0.200 |
Why?
|
| Nitrites | 1 | 2002 | 81 | 0.200 |
Why?
|
| Air Pollution, Indoor | 1 | 2024 | 145 | 0.200 |
Why?
|
| Proteomics | 2 | 2020 | 985 | 0.200 |
Why?
|
| Sertraline | 2 | 2013 | 29 | 0.200 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2022 | 13 | 0.200 |
Why?
|
| Sudden Infant Death | 1 | 2022 | 27 | 0.200 |
Why?
|
| Interdisciplinary Research | 1 | 2022 | 26 | 0.200 |
Why?
|
| Meconium Aspiration Syndrome | 3 | 2015 | 11 | 0.200 |
Why?
|
| Achievement | 1 | 2022 | 57 | 0.200 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 4 | 2006 | 22 | 0.200 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 676 | 0.200 |
Why?
|
| Angiography | 7 | 2002 | 199 | 0.190 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 58 | 0.190 |
Why?
|
| Young Adult | 10 | 2023 | 12286 | 0.190 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 45 | 0.190 |
Why?
|
| Uterus | 1 | 2002 | 204 | 0.190 |
Why?
|
| Receptor, Endothelin A | 5 | 2000 | 62 | 0.190 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 14 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2021 | 52 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 2270 | 0.180 |
Why?
|
| Transcription Factors | 3 | 2023 | 1634 | 0.180 |
Why?
|
| Prevalence | 4 | 2021 | 2540 | 0.180 |
Why?
|
| Amino Acids, Dicarboxylic | 1 | 2020 | 12 | 0.180 |
Why?
|
| Milrinone | 1 | 2021 | 29 | 0.180 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 58 | 0.180 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 34 | 0.180 |
Why?
|
| Emergency Treatment | 1 | 2002 | 116 | 0.180 |
Why?
|
| Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.180 |
Why?
|
| Mice | 9 | 2015 | 16543 | 0.180 |
Why?
|
| Pneumonia | 2 | 2022 | 612 | 0.180 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 70 | 0.180 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2000 | 49 | 0.170 |
Why?
|
| Trust | 1 | 2021 | 116 | 0.170 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 274 | 0.170 |
Why?
|
| Causality | 2 | 2018 | 114 | 0.170 |
Why?
|
| Gastroesophageal Reflux | 2 | 2022 | 240 | 0.170 |
Why?
|
| Interactive Ventilatory Support | 1 | 2020 | 2 | 0.170 |
Why?
|
| Stress, Mechanical | 5 | 2019 | 470 | 0.170 |
Why?
|
| Microbiota | 2 | 2018 | 724 | 0.170 |
Why?
|
| Current Procedural Terminology | 1 | 2020 | 12 | 0.170 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 252 | 0.170 |
Why?
|
| Quinoxalines | 2 | 2011 | 64 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1366 | 0.170 |
Why?
|
| Colony-Forming Units Assay | 2 | 2009 | 89 | 0.170 |
Why?
|
| Random Allocation | 1 | 2020 | 351 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 543 | 0.170 |
Why?
|
| Heart Function Tests | 1 | 2019 | 61 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 2668 | 0.170 |
Why?
|
| Transportation of Patients | 2 | 2002 | 50 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 150 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2016 | 2770 | 0.160 |
Why?
|
| Morphogenesis | 2 | 2013 | 159 | 0.160 |
Why?
|
| Blood Flow Velocity | 4 | 2019 | 413 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 1002 | 0.160 |
Why?
|
| Potassium Channel Blockers | 1 | 1999 | 35 | 0.160 |
Why?
|
| Scurvy | 1 | 2019 | 14 | 0.160 |
Why?
|
| Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.160 |
Why?
|
| Colorado | 5 | 2017 | 4443 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 57 | 0.160 |
Why?
|
| Respiratory Tract Infections | 3 | 2021 | 372 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 326 | 0.160 |
Why?
|
| Intubation, Intratracheal | 3 | 2017 | 241 | 0.150 |
Why?
|
| Vitamin A | 3 | 2019 | 55 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2020 | 92 | 0.150 |
Why?
|
| Maternal Exposure | 2 | 2012 | 173 | 0.150 |
Why?
|
| Receptors, Estrogen | 1 | 2001 | 423 | 0.150 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 1504 | 0.150 |
Why?
|
| Constriction | 3 | 2008 | 44 | 0.150 |
Why?
|
| Coculture Techniques | 2 | 2016 | 217 | 0.150 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 22 | 0.150 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 3042 | 0.150 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 25 | 0.150 |
Why?
|
| Placental Insufficiency | 2 | 2014 | 111 | 0.150 |
Why?
|
| Incidence | 6 | 2015 | 2634 | 0.150 |
Why?
|
| Elastin | 2 | 2015 | 78 | 0.150 |
Why?
|
| Serum Albumin | 3 | 1992 | 145 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 14 | 0.150 |
Why?
|
| Phosphorylation | 3 | 2015 | 1685 | 0.150 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 336 | 0.150 |
Why?
|
| Air | 2 | 2009 | 36 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2000 | 330 | 0.150 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2017 | 520 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 85 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2019 | 1282 | 0.140 |
Why?
|
| Gene Deletion | 1 | 2019 | 374 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2007 | 221 | 0.140 |
Why?
|
| Refractometry | 1 | 2017 | 28 | 0.140 |
Why?
|
| Education, Medical | 1 | 2020 | 241 | 0.140 |
Why?
|
| Stroke Volume | 2 | 2018 | 587 | 0.140 |
Why?
|
| Respiratory System | 1 | 2018 | 153 | 0.140 |
Why?
|
| Ventilators, Mechanical | 3 | 2021 | 58 | 0.140 |
Why?
|
| Optical Imaging | 1 | 2017 | 56 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 259 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2018 | 90 | 0.140 |
Why?
|
| Flow Cytometry | 2 | 2012 | 1146 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1100 | 0.140 |
Why?
|
| Dysbiosis | 1 | 2018 | 166 | 0.140 |
Why?
|
| Retinal Vessels | 1 | 2017 | 64 | 0.140 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 278 | 0.140 |
Why?
|
| Methemoglobin | 2 | 1993 | 20 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 237 | 0.140 |
Why?
|
| Collagen Type XVIII | 1 | 2016 | 4 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 106 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 1997 | 141 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2021 | 868 | 0.130 |
Why?
|
| Altitude Sickness | 1 | 2018 | 138 | 0.130 |
Why?
|
| Dietary Supplements | 3 | 2019 | 533 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2013 | 328 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 37 | 0.130 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.130 |
Why?
|
| Scimitar Syndrome | 1 | 2016 | 9 | 0.130 |
Why?
|
| Inflammation | 3 | 2021 | 2694 | 0.130 |
Why?
|
| Neutrophils | 3 | 2004 | 1203 | 0.130 |
Why?
|
| Family | 1 | 2020 | 650 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.130 |
Why?
|
| Hemoptysis | 1 | 2016 | 35 | 0.130 |
Why?
|
| Social Class | 1 | 2018 | 256 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 338 | 0.130 |
Why?
|
| Veins | 1 | 2016 | 60 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2015 | 15 | 0.130 |
Why?
|
| Cell Adhesion | 2 | 2016 | 452 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 171 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 501 | 0.120 |
Why?
|
| Survivors | 1 | 2019 | 458 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 404 | 0.120 |
Why?
|
| Calcifediol | 1 | 2015 | 33 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 1999 | 715 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2494 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 786 | 0.120 |
Why?
|
| Microvessels | 1 | 2016 | 79 | 0.120 |
Why?
|
| Probability | 2 | 2008 | 313 | 0.120 |
Why?
|
| Genetic Counseling | 1 | 2015 | 72 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3334 | 0.120 |
Why?
|
| Aging | 4 | 2007 | 1767 | 0.120 |
Why?
|
| Respiration | 5 | 2018 | 191 | 0.120 |
Why?
|
| Interleukin-1 | 1 | 1999 | 972 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2007 | 345 | 0.120 |
Why?
|
| Indiana | 1 | 2015 | 33 | 0.120 |
Why?
|
| Retina | 1 | 2017 | 277 | 0.120 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 57 | 0.120 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 19 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 178 | 0.120 |
Why?
|
| Cell Division | 2 | 2007 | 800 | 0.120 |
Why?
|
| Nitroprusside | 2 | 2011 | 67 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2016 | 224 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 5270 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 85 | 0.110 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 171 | 0.110 |
Why?
|
| Arteriovenous Fistula | 1 | 2014 | 37 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 957 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1701 | 0.110 |
Why?
|
| Contrast Media | 1 | 2017 | 387 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2019 | 525 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 772 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 1204 | 0.110 |
Why?
|
| Sulfur | 1 | 2014 | 50 | 0.110 |
Why?
|
| Taurine | 1 | 2014 | 41 | 0.110 |
Why?
|
| Developmental Disabilities | 2 | 2014 | 254 | 0.110 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2014 | 69 | 0.110 |
Why?
|
| Vasopressins | 1 | 2014 | 64 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 68 | 0.110 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 493 | 0.110 |
Why?
|
| Embryo, Mammalian | 1 | 2014 | 223 | 0.110 |
Why?
|
| Schools, Medical | 1 | 2015 | 128 | 0.110 |
Why?
|
| Glycopeptides | 1 | 1994 | 44 | 0.110 |
Why?
|
| Immunologic Techniques | 3 | 1999 | 39 | 0.110 |
Why?
|
| Transcriptome | 1 | 2020 | 871 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1192 | 0.110 |
Why?
|
| Cardiac Output | 3 | 2017 | 157 | 0.110 |
Why?
|
| Vascular Remodeling | 1 | 2015 | 186 | 0.110 |
Why?
|
| Collagen | 2 | 2014 | 433 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 1995 | 223 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 130 | 0.110 |
Why?
|
| Homocystinuria | 1 | 2014 | 70 | 0.110 |
Why?
|
| Sheep, Domestic | 1 | 2013 | 34 | 0.110 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2004 | 79 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 848 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1854 | 0.100 |
Why?
|
| Acute Disease | 5 | 2005 | 978 | 0.100 |
Why?
|
| Pain | 1 | 2019 | 761 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1516 | 0.100 |
Why?
|
| Hypotension | 1 | 2014 | 118 | 0.100 |
Why?
|
| Cysteine | 1 | 2014 | 190 | 0.100 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2013 | 55 | 0.100 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 53 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2013 | 54 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 210 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 327 | 0.100 |
Why?
|
| Staining and Labeling | 4 | 1997 | 142 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 837 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 77 | 0.100 |
Why?
|
| Diastole | 2 | 2015 | 151 | 0.100 |
Why?
|
| Career Mobility | 1 | 2013 | 68 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 120 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 65 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2020 | 966 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2013 | 113 | 0.100 |
Why?
|
| Streptococcus agalactiae | 1 | 1993 | 91 | 0.100 |
Why?
|
| Airway Obstruction | 2 | 1984 | 157 | 0.100 |
Why?
|
| Cadaver | 1 | 2013 | 332 | 0.100 |
Why?
|
| Global Health | 2 | 2019 | 317 | 0.100 |
Why?
|
| Pancreas | 1 | 2014 | 307 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2017 | 1101 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 985 | 0.100 |
Why?
|
| Hysterotomy | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cell Aggregation | 1 | 2011 | 25 | 0.100 |
Why?
|
| Eicosanoids | 1 | 1992 | 56 | 0.100 |
Why?
|
| Receptors, Serotonin | 1 | 2011 | 32 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 204 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 73 | 0.090 |
Why?
|
| DNA Primers | 1 | 2012 | 522 | 0.090 |
Why?
|
| Suction | 1 | 2011 | 32 | 0.090 |
Why?
|
| Bacterial Load | 1 | 2011 | 67 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 145 | 0.090 |
Why?
|
| Carbon Dioxide | 3 | 2000 | 261 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 193 | 0.090 |
Why?
|
| Length of Stay | 2 | 2016 | 1126 | 0.090 |
Why?
|
| Guanidines | 3 | 2001 | 35 | 0.090 |
Why?
|
| Receptor, Insulin | 1 | 2011 | 99 | 0.090 |
Why?
|
| Hydrogels | 1 | 2018 | 634 | 0.090 |
Why?
|
| Antibodies | 1 | 1993 | 392 | 0.090 |
Why?
|
| Fluoxetine | 1 | 2011 | 53 | 0.090 |
Why?
|
| RNA, Ribosomal | 1 | 2011 | 161 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2015 | 727 | 0.090 |
Why?
|
| Primary Cell Culture | 1 | 2011 | 159 | 0.090 |
Why?
|
| RNA Interference | 1 | 2012 | 448 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 319 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 5355 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1423 | 0.090 |
Why?
|
| Metagenome | 1 | 2011 | 137 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1435 | 0.090 |
Why?
|
| RNA, Bacterial | 1 | 2011 | 182 | 0.090 |
Why?
|
| Protein Binding | 1 | 2016 | 2086 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 238 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 822 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2001 | 67 | 0.090 |
Why?
|
| Rats, Inbred Strains | 2 | 2001 | 365 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 839 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 424 | 0.090 |
Why?
|
| Macrophages | 1 | 2018 | 1452 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 363 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 1992 | 474 | 0.080 |
Why?
|
| Gelatin | 2 | 2000 | 40 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 853 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2013 | 674 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 310 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2001 | 131 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 503 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 1990 | 133 | 0.080 |
Why?
|
| Cell Shape | 1 | 2009 | 54 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2001 | 54 | 0.080 |
Why?
|
| Death, Sudden | 1 | 1989 | 25 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1694 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2001 | 80 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 418 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2020 | 1545 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 316 | 0.080 |
Why?
|
| Respirovirus Infections | 1 | 1988 | 23 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2013 | 685 | 0.080 |
Why?
|
| Cesarean Section | 3 | 2000 | 180 | 0.080 |
Why?
|
| Research | 1 | 2012 | 413 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 730 | 0.080 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2008 | 3 | 0.080 |
Why?
|
| Endoglin | 1 | 2008 | 19 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2010 | 117 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2020 | 987 | 0.080 |
Why?
|
| Pressure | 2 | 2002 | 238 | 0.080 |
Why?
|
| Hyponatremia | 1 | 1988 | 40 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 48 | 0.080 |
Why?
|
| Biopsy | 2 | 2024 | 1093 | 0.080 |
Why?
|
| Meclofenamic Acid | 3 | 2001 | 10 | 0.080 |
Why?
|
| Heart Failure | 1 | 2021 | 2142 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2014 | 792 | 0.070 |
Why?
|
| Algorithms | 4 | 2024 | 1626 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 1988 | 141 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 287 | 0.070 |
Why?
|
| Purinones | 2 | 1998 | 4 | 0.070 |
Why?
|
| Heart Rate, Fetal | 2 | 1999 | 20 | 0.070 |
Why?
|
| Time | 2 | 2005 | 75 | 0.070 |
Why?
|
| Staphylococcus | 2 | 2017 | 74 | 0.070 |
Why?
|
| Tolazoline | 1 | 1986 | 3 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 932 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2008 | 174 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 128 | 0.070 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2006 | 7 | 0.070 |
Why?
|
| Norepinephrine | 1 | 1987 | 218 | 0.070 |
Why?
|
| Diuretics | 2 | 2019 | 74 | 0.070 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1986 | 6 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2000 | 151 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 2073 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2005 | 327 | 0.070 |
Why?
|
| Partial Pressure | 2 | 2002 | 29 | 0.070 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2006 | 53 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2006 | 18 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2006 | 77 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1998 | 354 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2008 | 728 | 0.060 |
Why?
|
| Liver | 1 | 2014 | 1832 | 0.060 |
Why?
|
| Thiophenes | 1 | 2006 | 118 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 1998 | 513 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 1989 | 516 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2426 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 271 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 245 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2005 | 120 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2004 | 46 | 0.060 |
Why?
|
| Cardiomegaly | 3 | 1997 | 172 | 0.060 |
Why?
|
| Heart | 2 | 2000 | 650 | 0.060 |
Why?
|
| Myocardium | 2 | 2000 | 981 | 0.060 |
Why?
|
| Blood Gas Analysis | 3 | 2000 | 71 | 0.060 |
Why?
|
| Calcium | 3 | 1996 | 1173 | 0.060 |
Why?
|
| Postoperative Period | 2 | 1998 | 319 | 0.060 |
Why?
|
| Methacholine Chloride | 1 | 2024 | 51 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 421 | 0.060 |
Why?
|
| Heart Atria | 1 | 2004 | 126 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 2 | 2000 | 25 | 0.060 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 7 | 0.060 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 85 | 0.060 |
Why?
|
| Parturition | 1 | 2004 | 66 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 295 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 84 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 78 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1967 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1840 | 0.050 |
Why?
|
| Infant Death | 1 | 2022 | 5 | 0.050 |
Why?
|
| Chromones | 1 | 2002 | 46 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 30 | 0.050 |
Why?
|
| Hematocrit | 2 | 2000 | 93 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 82 | 0.050 |
Why?
|
| Foreign Bodies | 1 | 1984 | 102 | 0.050 |
Why?
|
| Arteriovenous Malformations | 1 | 2022 | 29 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2021 | 113 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 291 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 48 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2022 | 89 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2022 | 509 | 0.050 |
Why?
|
| Injections | 2 | 1994 | 174 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 861 | 0.050 |
Why?
|
| Nifedipine | 1 | 2002 | 28 | 0.050 |
Why?
|
| Mosaicism | 1 | 2022 | 71 | 0.050 |
Why?
|
| Morpholines | 1 | 2002 | 126 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2022 | 180 | 0.050 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2002 | 140 | 0.050 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 25 | 0.050 |
Why?
|
| Heterozygote | 2 | 2019 | 268 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 367 | 0.050 |
Why?
|
| Fetal Hypoxia | 1 | 2022 | 51 | 0.050 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 13 | 0.050 |
Why?
|
| Ciliary Motility Disorders | 1 | 2021 | 23 | 0.050 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2024 | 232 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2001 | 47 | 0.050 |
Why?
|
| Placentation | 1 | 2021 | 44 | 0.050 |
Why?
|
| Amidines | 1 | 2001 | 16 | 0.050 |
Why?
|
| Benzylamines | 1 | 2001 | 42 | 0.050 |
Why?
|
| Quality of Life | 2 | 2010 | 2706 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2001 | 77 | 0.050 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 2000 | 10 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 148 | 0.050 |
Why?
|
| Insulin | 1 | 2011 | 2311 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 2000 | 15 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 172 | 0.040 |
Why?
|
| Ligands | 1 | 2003 | 614 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2001 | 296 | 0.040 |
Why?
|
| Evidence-Based Medicine | 4 | 2007 | 729 | 0.040 |
Why?
|
| Cyclohexanes | 1 | 2000 | 22 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2000 | 79 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 3671 | 0.040 |
Why?
|
| Plethysmography | 1 | 2001 | 109 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 359 | 0.040 |
Why?
|
| Thalidomide | 1 | 2000 | 30 | 0.040 |
Why?
|
| Perfusion | 2 | 1994 | 191 | 0.040 |
Why?
|
| Sesquiterpenes | 1 | 2000 | 54 | 0.040 |
Why?
|
| Heart Septum | 1 | 2000 | 28 | 0.040 |
Why?
|
| Vaping | 1 | 2021 | 57 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2001 | 232 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2001 | 370 | 0.040 |
Why?
|
| Barium | 1 | 2000 | 27 | 0.040 |
Why?
|
| Exercise Test | 2 | 2019 | 619 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2000 | 93 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 333 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 369 | 0.040 |
Why?
|
| Pediatricians | 1 | 2021 | 133 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2000 | 68 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 127 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2000 | 27 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2000 | 74 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 202 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 50 | 0.040 |
Why?
|
| Fever | 1 | 2001 | 301 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2002 | 162 | 0.040 |
Why?
|
| Ventricular Pressure | 2 | 2015 | 44 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 190 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
|
| Indazoles | 1 | 2000 | 67 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 52 | 0.040 |
Why?
|
| Charybdotoxin | 1 | 1999 | 6 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 412 | 0.040 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 17 | 0.040 |
Why?
|
| Gingiva | 1 | 2019 | 25 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 23 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 81 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 1999 | 65 | 0.040 |
Why?
|
| Societies | 1 | 2019 | 37 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 859 | 0.040 |
Why?
|
| Atrial Function, Right | 1 | 1998 | 12 | 0.040 |
Why?
|
| Caffeine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 108 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2001 | 362 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 41 | 0.040 |
Why?
|
| Progestins | 1 | 2019 | 78 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 2019 | 59 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 1020 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 89 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 172 | 0.040 |
Why?
|
| North America | 1 | 2019 | 289 | 0.040 |
Why?
|
| Air Pollution | 1 | 2021 | 225 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 1999 | 295 | 0.040 |
Why?
|
| Asphyxia Neonatorum | 1 | 1998 | 17 | 0.040 |
Why?
|
| Nutritional Status | 2 | 1992 | 325 | 0.040 |
Why?
|
| Nose | 1 | 1998 | 64 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 120 | 0.040 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.040 |
Why?
|
| Thiazines | 1 | 1998 | 9 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 636 | 0.040 |
Why?
|
| Long-Term Care | 1 | 1998 | 88 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 215 | 0.040 |
Why?
|
| Masks | 1 | 1998 | 59 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 628 | 0.040 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2018 | 75 | 0.040 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2017 | 35 | 0.040 |
Why?
|
| Catheterization | 1 | 1998 | 176 | 0.040 |
Why?
|
| Phentolamine | 2 | 1987 | 14 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 269 | 0.040 |
Why?
|
| Medical Records | 1 | 1998 | 170 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 376 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 244 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 357 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1997 | 90 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 233 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 61 | 0.030 |
Why?
|
| Travel | 1 | 2018 | 123 | 0.030 |
Why?
|
| Shear Strength | 1 | 2017 | 68 | 0.030 |
Why?
|
| Leg | 1 | 2019 | 241 | 0.030 |
Why?
|
| Methylene Blue | 1 | 1996 | 24 | 0.030 |
Why?
|
| Biological Products | 1 | 2000 | 202 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 139 | 0.030 |
Why?
|
| Education | 1 | 2017 | 98 | 0.030 |
Why?
|
| Iron | 1 | 2019 | 285 | 0.030 |
Why?
|
| Indomethacin | 1 | 1996 | 78 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2047 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1997 | 74 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 173 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1194 | 0.030 |
Why?
|
| Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 518 | 0.030 |
Why?
|
| Growth | 2 | 1997 | 57 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 308 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 671 | 0.030 |
Why?
|
| Adenosine | 1 | 1998 | 213 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 313 | 0.030 |
Why?
|
| Fellowships and Scholarships | 2 | 2010 | 271 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 52 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 321 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 89 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 2842 | 0.030 |
Why?
|
| Parents | 1 | 2024 | 1301 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 8 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2004 | 642 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1221 | 0.030 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 24 | 0.030 |
Why?
|
| Arterioles | 1 | 1995 | 42 | 0.030 |
Why?
|
| Theophylline | 1 | 1995 | 66 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 757 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 82 | 0.030 |
Why?
|
| Phenylephrine | 1 | 1995 | 75 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1999 | 1858 | 0.030 |
Why?
|
| Catalase | 1 | 2015 | 122 | 0.030 |
Why?
|
| Cysteine Dioxygenase | 1 | 2014 | 3 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 30977 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2019 | 658 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 877 | 0.030 |
Why?
|
| Sepharose | 1 | 1994 | 33 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1994 | 9 | 0.030 |
Why?
|
| Frozen Sections | 1 | 1994 | 26 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1994 | 19 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 935 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2009 | 211 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 77 | 0.030 |
Why?
|
| Guanosine Monophosphate | 1 | 2013 | 7 | 0.030 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1993 | 11 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 784 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 158 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1993 | 79 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1542 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 169 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 5032 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 824 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2013 | 49 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 273 | 0.030 |
Why?
|
| Cromakalim | 1 | 1992 | 1 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 896 | 0.030 |
Why?
|
| Cytosol | 1 | 1993 | 210 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 487 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1289 | 0.030 |
Why?
|
| Glyburide | 1 | 1992 | 35 | 0.030 |
Why?
|
| Benzopyrans | 1 | 1992 | 31 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 575 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1992 | 20 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 328 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 575 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 718 | 0.020 |
Why?
|
| Verapamil | 2 | 1994 | 38 | 0.020 |
Why?
|
| Trypsinogen | 1 | 1991 | 9 | 0.020 |
Why?
|
| Venae Cavae | 1 | 1991 | 8 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1991 | 84 | 0.020 |
Why?
|
| Pharynx | 1 | 1991 | 56 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 1991 | 155 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 1990 | 26 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1991 | 20 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 63 | 0.020 |
Why?
|
| Vitamin E Deficiency | 1 | 1991 | 43 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 78 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1991 | 75 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 22035 | 0.020 |
Why?
|
| Vitamin A Deficiency | 1 | 1991 | 27 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 158 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 1013 | 0.020 |
Why?
|
| Pancreatin | 2 | 1991 | 5 | 0.020 |
Why?
|
| Muscle Development | 1 | 1991 | 103 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 1923 | 0.020 |
Why?
|
| Critical Care | 1 | 1995 | 547 | 0.020 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 41 | 0.020 |
Why?
|
| Accreditation | 1 | 2010 | 81 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2009 | 18 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2009 | 47 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7050 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 113 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1991 | 217 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 141 | 0.020 |
Why?
|
| Pulmonary Heart Disease | 1 | 1988 | 6 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1991 | 343 | 0.020 |
Why?
|
| Brain | 2 | 2017 | 2592 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 189 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 122 | 0.020 |
Why?
|
| Sheep Diseases | 1 | 1988 | 7 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2844 | 0.020 |
Why?
|
| Chest Wall Oscillation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1987 | 34 | 0.020 |
Why?
|
| Kinetics | 1 | 1991 | 1619 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1991 | 429 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cimetidine | 1 | 1986 | 13 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 58 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 1986 | 31 | 0.020 |
Why?
|
| Hypoproteinemia | 1 | 1986 | 4 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 615 | 0.020 |
Why?
|
| Epinephrine | 1 | 1987 | 180 | 0.020 |
Why?
|
| Pancreatic Extracts | 1 | 1985 | 2 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1985 | 4 | 0.020 |
Why?
|
| Pancrelipase | 1 | 1985 | 6 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2530 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 436 | 0.020 |
Why?
|
| Lipase | 1 | 1985 | 63 | 0.020 |
Why?
|
| Edema | 1 | 1986 | 127 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 863 | 0.010 |
Why?
|
| Anemia | 1 | 1986 | 155 | 0.010 |
Why?
|
| Failure to Thrive | 1 | 1984 | 29 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 1984 | 8 | 0.010 |
Why?
|
| Propranolol | 1 | 1984 | 49 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1986 | 236 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 325 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 480 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 261 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 164 | 0.010 |
Why?
|
| Heart Rate | 1 | 1986 | 807 | 0.010 |
Why?
|
| Child Health Services | 1 | 1984 | 184 | 0.010 |
Why?
|
| Ebstein Anomaly | 1 | 1981 | 6 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1981 | 47 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 602 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 46 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 51 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 125 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 70 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2000 | 83 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 137 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2000 | 16 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 108 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2000 | 104 | 0.010 |
Why?
|
| Vitamin E | 2 | 1991 | 118 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 241 | 0.010 |
Why?
|
| CREST Syndrome | 1 | 1999 | 6 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 248 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1999 | 44 | 0.010 |
Why?
|
| Monocrotaline | 1 | 1999 | 27 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1999 | 23 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 230 | 0.010 |
Why?
|
| Sex Factors | 1 | 1984 | 1947 | 0.010 |
Why?
|
| Homozygote | 1 | 1999 | 192 | 0.010 |
Why?
|
| Mass Screening | 1 | 1985 | 1121 | 0.010 |
Why?
|
| Frontal Bone | 1 | 1997 | 13 | 0.010 |
Why?
|
| Occipital Bone | 1 | 1997 | 19 | 0.010 |
Why?
|
| Cephalometry | 1 | 1997 | 32 | 0.010 |
Why?
|
| Child Development | 2 | 1997 | 451 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 274 | 0.010 |
Why?
|
| Body Height | 1 | 1997 | 191 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 186 | 0.010 |
Why?
|
| Fixatives | 1 | 1994 | 15 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 310 | 0.010 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1994 | 11 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2000 | 1059 | 0.010 |
Why?
|
| Ryanodine | 1 | 1994 | 14 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1994 | 57 | 0.010 |
Why?
|
| Manganese | 1 | 1994 | 61 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1994 | 205 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 159 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1993 | 92 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1992 | 52 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1991 | 51 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1993 | 207 | 0.010 |
Why?
|
| Sweat | 1 | 1991 | 46 | 0.010 |
Why?
|
| Anthropometry | 1 | 1992 | 205 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1991 | 115 | 0.010 |
Why?
|
| Phospholipid Ethers | 1 | 1991 | 7 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1992 | 131 | 0.010 |
Why?
|
| Polymers | 1 | 1994 | 475 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1991 | 255 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1992 | 302 | 0.010 |
Why?
|
| Hydroxycholecalciferols | 1 | 1989 | 3 | 0.010 |
Why?
|
| Infant Nutrition Disorders | 1 | 1989 | 11 | 0.010 |
Why?
|
| Vitamin K | 1 | 1989 | 42 | 0.010 |
Why?
|
| Solubility | 1 | 1989 | 233 | 0.000 |
Why?
|
| Energy Intake | 1 | 1992 | 453 | 0.000 |
Why?
|
| Breast Feeding | 1 | 1992 | 423 | 0.000 |
Why?
|
| Genotype | 1 | 1993 | 1834 | 0.000 |
Why?
|
| Lipids | 1 | 1989 | 614 | 0.000 |
Why?
|
| HIV Infections | 1 | 1999 | 2696 | 0.000 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1984 | 84 | 0.000 |
Why?
|
| Digoxin | 1 | 1981 | 30 | 0.000 |
Why?
|
| Furosemide | 1 | 1981 | 37 | 0.000 |
Why?
|